Cas13d wants to compete with Cas9 to benefit tumor patients by enhancing precision CAR T therapy

Hongbiao Ran; Jianxin Jiang; Ping Lin

doi:10.1002/mba2.86

MEDCOMM - Biomaterials and Applications ›› 2024, Vol. 3 ›› Issue (2) : 86 DOI: 10.1002/mba2.86

HIGHLIGHT

Cas13d wants to compete with Cas9 to benefit tumor patients by enhancing precision CAR T therapy

Hongbiao Ran ¹
, Jianxin Jiang ²^,^†
, Ping Lin ¹^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Hongbiao Ran, Jianxin Jiang, Ping Lin. Cas13d wants to compete with Cas9 to benefit tumor patients by enhancing precision CAR T therapy. MEDCOMM - Biomaterials and Applications, 2024, 3(2): 86 DOI:10.1002/mba2.86

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024 The Authors. MedComm - Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).